{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"100","value":"11.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response as assessed by RECIST 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment","id":"OG000","title":"Ixabepilone"}],"paramType":"NUMBER","populationDescription":"Eligible and Treated Patients. Measure of dispersion is 95% One-sided confidence Interval","reportingStatus":"POSTED","timeFrame":"Every other cycle for first 6 months; then every 3 months thereafter until completion of study treatment; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.1 cycle is 21 days","title":"Objective Tumor Response","type":"PRIMARY","unitOfMeasure":"percentage"}